TAMPA, Fla. -- Romark Laboratories, L.C. has expanded its ongoing research activity with AIDS-infected children in Zambia as part of its continuing efforts to broaden the base of knowledge relating to the impact of protozoal infections during treatment programs.
Romark initiated research in Zambia during 2000-2001 with AIDS-infected children as it sought to determine what drugs would minimize or eliminate the side effect, persistent diarrhea, which is caused by the waterborne protozoan, Cryptosporidium. That research, which was eventually published in the British journal, The Lancet, showed that a new drug, nitazoxanide, significantly reduced the duration of diarrhea and the rate of death in malnourished children infected with Cryptosporidium. (Nitazoxanide is now marketed in the U.S. for treatment of pediatric diarrhea under the name Alinia.)
Marc Ayers, president of Romark Laboratories, said the decision to move forward on expanded research was prompted by the realization that nitazoxanide (Alinia) has the potential for broad application in the treatments of multiple illnesses where waterborne protozoan such as Cryptosporidium and Giardiasis are perceived to be the cause.
"When the Food and Drug Administration approved Alinia for the treatment of persistent diarrhea in children in 2002, it was the first new drug of this type to come to market in 40 years. We believe there are many other related illnesses that can be treated with this drug," he added.
Ayers said the research effort is focused in the African nation of Zambia because of the large population of malnourished AIDS-infected children, which in turn provides a consistent and controlled study group. The research effort is being coordinated through the University of London. The study is taking place at the University Teaching Hospital in Lusaka, Zambia.
"Our hope is to provide the world new applications for nitazoxanide. Waterborne protozoal infections are one of the world's leading causes of death, especially among children," Ayers said.
Romark Laboratories is a privately owned, research-based pharmaceutical company based in Tampa, Fla., dedicated to the discovery and development of innovative new pharmaceutical products for treating infectious diseases and cancer.
Source: Romark Laboratories, L.C.
Strengthening Infection Prevention: APIC Urges Support From HHS Secretary Kennedy
February 13th 2025APIC congratulates Secretary Robert F. Kennedy, Jr on his appointment and urges support for infection prevention priorities, including NHSN funding, workforce development, nursing home IPC improvements, medical device cleaning standards, and global health collaboration.
Universities and States Sue NIH Over Funding Cuts, Federal Judge Temporarily Halts Policy
February 13th 2025Twelve universities and 3 education groups filed a lawsuit against the NIH and HHS, challenging a 15% cap on research grant funding. A federal judge issued a temporary restraining order, halting the cuts while litigation proceeds. A hearing is set for February 21, 2025, and states and institutions are pushing for permanent relief.
Second Strain of Bird Flu Found in US Dairy Cows: What It Means for Infection Prevention and Control
February 7th 2025A new H5N1 strain was found in Nevada dairy cows, challenging earlier transmission theories. This raises concerns about animal vulnerability, human health risks, and food safety. Experts emphasize the need for improved surveillance, biosecurity, and cross-sector collaboration to contain the virus spread.